The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasmsThe clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
- Other Titles
- The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
- Authors
- Seug Yun Yoon; Jong-Ho Won
- Issue Date
- Apr-2021
- Publisher
- 대한혈액학회
- Keywords
- Myeloproliferative disorder; Interferon alpha; Therapy; .
- Citation
- Blood Research, v.56, pp.44 - 50
- Journal Title
- Blood Research
- Volume
- 56
- Start Page
- 44
- End Page
- 50
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19335
- DOI
- 10.5045/br.2021.2020334
- ISSN
- 2287-979X
- Abstract
- Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell malignancies.
Chronic inflammation and a dysregulated immune system are central to the pathogenesis and progression of MPNs. Interferon alpha (IFN) was first used for the treatment of MPNs approximately 40 years ago. It has significant antiviral effects and plays a role in anti-proliferative, pro-apoptotic, and immunomodulatory responses. IFN is an effective drug that can simultaneously induce significant rates of clinical, hematological, molecular, and histopathological responses, suggesting that the disease may be cured in some patients. However, its frequent dosage and toxicity profile are major barriers to its widespread use. Pegylated IFN (peg-IFN), and more recently, ropeginterferon alpha-2b (ropeg-IFN-2b), are expected to overcome these drawbacks. The objective of this article is to discuss the clinical role of IFN in Philadelphia-negative MPNs through a review of recent studies. In particular, it is expected that new IFNs, such as peg-IFN and ropeg- IFN-2b, with lower rates of discontinuation due to fewer adverse effects, will play important clinical roles.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19335)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.